Gedatolisib
Sign in to save this workspacePrimary targets: PI3K, MTOR_FRAP1 · FDA status: Phase III FDA Trials
Selectivity scorecard
KISS
99.75
Gini
0.611
CATDS
0.044
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Gedatolisib. Strongest target: MTOR_FRAP1 at 95.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | MTOR_FRAP1 | 95.0% | 5.0% |
| 2 | DNA_PK | 73.5% | 26.5% |
| 3 | BRAF | 56.5% | 43.5% |
| 4 | TAOK2_TAO1 | 48.6% | 51.4% |
| 5 | RAF1 | 34.9% | 65.1% |
| 6 | ARAF | 31.9% | 68.1% |
| 7 | EIF2AK2 | 23.8% | 76.2% |
| 8 | CK1EPSILON | 21.0% | 79.0% |
| 9 | MYO3B | 20.3% | 79.7% |
| 10 | NEK9 | 19.0% | 81.0% |
| 11 | CK1G1 | 18.1% | 81.9% |
| 12 | LOK_STK10 | 18.0% | 82.0% |
| 13 | PKCB1 | 17.6% | 82.4% |
| 14 | SNRK | 17.0% | 83.0% |
| 15 | CDK9_CYCLIN_T2 | 16.4% | 83.6% |
| 16 | RIPK5 | 16.3% | 83.7% |
| 17 | SLK_STK2 | 15.6% | 84.4% |
| 18 | LATS2 | 15.6% | 84.4% |
| 19 | TAOK1 | 15.5% | 84.5% |
| 20 | DMPK2 | 15.4% | 84.6% |
Selectivity landscape
Where Gedatolisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Gedatolisib.
Atlas insights for Gedatolisib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 575.05 | |
| ALLOGRAFT_REJECTION | 1140.69 | |
| ANDROGEN_RESPONSE | 512.53 | |
| ANGIOGENESIS | 212.60 | |
| APICAL_JUNCTION | 1389.95 | |
| APICAL_SURFACE | 158.13 | |
| APOPTOSIS | 1410.09 | |
| BILE_ACID_METABOLISM | 158.49 | |
| CHOLESTEROL_HOMEOSTASIS | 148.24 | |
| COAGULATION | 144.97 | |
| COMPLEMENT | 833.45 | |
| DNA_REPAIR | 477.55 | |
| E2F_TARGETS | 1499.64 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 542.33 | |
| ESTROGEN_RESPONSE_EARLY | 847.20 | |
| ESTROGEN_RESPONSE_LATE | 720.27 | |
| FATTY_ACID_METABOLISM | 84.17 | |
| G2M_CHECKPOINT | 1489.96 | |
| GLYCOLYSIS | 566.84 | |
| HEDGEHOG_SIGNALING | 211.11 | |
| HEME_METABOLISM | 586.45 | |
| HYPOXIA | 785.48 | |
| IL2_STAT5_SIGNALING | 662.46 | |
| IL6_JAK_STAT3_SIGNALING | 815.74 | |
| INFLAMMATORY_RESPONSE | 1090.02 | |
| INTERFERON_ALPHA_RESPONSE | 205.26 | |
| INTERFERON_GAMMA_RESPONSE | 1164.00 | |
| KRAS_SIGNALING_DN | 326.32 | |
| KRAS_SIGNALING_UP | 513.65 | |
| MITOTIC_SPINDLE | 1333.07 | |
| MTORC1_SIGNALING | 860.72 | |
| MYC_TARGETS_V1 | 971.99 | |
| MYC_TARGETS_V2 | 276.39 | |
| MYOGENESIS | 768.19 | |
| NOTCH_SIGNALING | 86.79 | |
| OXIDATIVE_PHOSPHORYLATION | 161.51 | |
| P53_PATHWAY | 872.84 | |
| PANCREAS_BETA_CELLS | 143.36 | |
| PEROXISOME | 252.20 | |
| PI3K_AKT_MTOR_SIGNALING | 1803.30 | |
| PROTEIN_SECRETION | 442.49 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 105.95 | |
| SPERMATOGENESIS | 551.96 | |
| TGF_BETA_SIGNALING | 454.63 | |
| TNFA_SIGNALING_VIA_NFKB | 1284.31 | |
| UNFOLDED_PROTEIN_RESPONSE | 390.11 | |
| UV_RESPONSE_DN | 1035.63 | |
| UV_RESPONSE_UP | 705.66 | |
| WNT_BETA_CATENIN_SIGNALING | 519.15 | |
| XENOBIOTIC_METABOLISM | 331.94 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.869 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.865 |
| SRR12202498 | — | 0.840 |
| SRR1443713 | GTEX | 0.839 |
| SRR23303752 | — | 0.834 |
Annotations
Sign in to read and post annotations.
Loading…